Investors With Losses In Actinium Pharmaceuticals Inc Can Join Fraud Investigation With The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / August 19, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Actinium Pharmaceuticals, Inc. ("Actinium" or "the Company") (NYSE American:ATNM) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
ATNM SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Actinium Pharmaceuticals, Inc. and Encourages Investors to Contact the Firm Today!
NEW YORK, NY / ACCESSWIRE / August 19, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Actinium Pharmaceuticals, Inc. ("Actinium" or "the Company") (NYSE:ATNM). Investors who purchased Actinium securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ATNM.
An Investigation Has Commenced on Behalf of Actinium Pharmaceuticals, Inc. Shareholders. Contact Levi & Korsinsky to Discuss your ATNM Losses.
NEW YORK, NY / ACCESSWIRE / August 19, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Actinium Pharmaceuticals, Inc. ("Actinium") (NYSE:ATNM) concerning possible violations of federal securities laws. Actinium issued a press release on August 5, 2024, "announc[ing] a regulatory update on the Company's planned Biologics License Application (‘BLA') filing for Iomab-B in patients with active relapsed or refractory acute myeloid leukemia (‘r/r AML').
Shareholders In Actinium Pharmaceuticals Inc Invited To Participate In Fraud Investigation With The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / August 18, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Actinium Pharmaceuticals, Inc. ("Actinium" or "the Company") (NYSE American:ATNM) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
ATNM INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Actinium Pharmaceuticals, Inc. and Encourages Investors to Contact the Firm Today!
NEW YORK, NY / ACCESSWIRE / August 18, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Actinium Pharmaceuticals, Inc. ("Actinium" or "the Company") (NYSE:ATNM). Investors who purchased Actinium securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ATNM.
Actinium Pharmaceuticals Inc Investors Invited To Partake In Fraud Investigation With The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / August 17, 2024 / The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Actinium Pharmaceuticals, Inc. ("Actinium" or "the Company") (NYSE American:ATNM) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Actinium Pharmaceuticals Inc Stakeholders Encouraged To Join In Fraud Investigation With The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / August 16, 2024 / The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Actinium Pharmaceuticals, Inc. ("Actinium" or "the Company") (NYSE American:ATNM) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
ATNM SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Actinium Pharmaceuticals, Inc. and Encourages Stockholders to Contact the Firm!
NEW YORK, NY / ACCESSWIRE / August 16, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Actinium Pharmaceuticals, Inc. ("Actinium" or "the Company") (NYSE:ATNM). Investors who purchased Actinium securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ATNM.
Actinium Pharmaceuticals, Inc. (ATNM) Investors with Losses are Urged to Contact Levi & Korsinsky to Discuss Their Rights
NEW YORK, NY / ACCESSWIRE / August 16, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Actinium Pharmaceuticals, Inc. ("Actinium") (NYSE:ATNM) concerning possible violations of federal securities laws. Actinium issued a press release on August 5, 2024, "announc[ing] a regulatory update on the Company's planned Biologics License Application (‘BLA') filing for Iomab-B in patients with active relapsed or refractory acute myeloid leukemia (‘r/r AML').
Actinium Pharmaceuticals Inc Investors Encouraged To Join In Fraud Investigation With The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / August 15, 2024 / The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Actinium Pharmaceuticals, Inc. ("Actinium" or "the Company") (NYSE American: ATNM ) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
ATNM INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Actinium Pharmaceuticals, Inc. and Encourages Stockholders to Contact the Firm!
NEW YORK, NY / ACCESSWIRE / August 15, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Actinium Pharmaceuticals, Inc. ("Actinium" or "the Company") (NYSE:ATNM). Investors who purchased Actinium securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ATNM.
Levi & Korsinsky Reminds Shareholders of an Investigation into Actinium Pharmaceuticals, Inc. (ATNM) Regarding Potential Securities Fraud Allegations
NEW YORK, NY / ACCESSWIRE / August 15, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Actinium Pharmaceuticals, Inc. ("Actinium") (NYSE:ATNM) concerning possible violations of federal securities laws. Actinium issued a press release on August 5, 2024, "announc[ing] a regulatory update on the Company's planned Biologics License Application (‘BLA') filing for Iomab-B in patients with active relapsed or refractory acute myeloid leukemia (‘r/r AML').
